Biogen, AbbVie yank MS drug Zinbryta off the market in the wake of encephalitis cases
The marketing effort for the MS drug Zinbryta (daclizumab) imploded today after European regulators flagged a lethal safety warning over cases of inflammatory encephalitis and meningoencephalitis. Biogen $BIIB and AbbVie $ABBV, which had been looking to spend this year building sales of the MS treatment, are now yanking it off the market in the EU and the US.
“Given the nature and complexity of adverse events being reported, characterizing the evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated,” the companies said in a statement. “Therefore, Biogen and AbbVie believe it is in the best interest of patients to voluntarily withdraw worldwide marketing authorizations for Zinbryta.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.